Ocrelizumab, an alternative to rituximab in refractory pemphigus vulgaris management.
Eduardo de la Rosa-FernándezI Loizate-SarrionandiaJ González-RodríguezMaría Herrero-MoyanoRicardo Fernández-de-MisaJ Suárez-HernándezPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)